Holen Sie sich die Stockscreener-App
485.62
3.25%
-14.87
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Reshma Kewalramani named among Time magazine's 100 most influential people - Firstpost
Vertex’s Attempt to Redefine AKS Falls Short: Key Insights for Pharma Manufacturers - ArentFox Schiff
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $617 From $615, Maintains Buy Rating - MarketScreener
Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce - The Motley Fool
Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF R - GuruFocus
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? - AOL.com
Lobbying Update: $20,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
Pharma Tariffs Are Coming. Investors Underestimate the Risk. - Barron's
Vertex researcher recognized by the Canada Gairdner International Award - Vertex Pharmaceuticals
CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canad - GuruFocus
Vertex Researcher, Paul Negulescu Ph.D., Receives The 2025 Canada Gairdner International Award For Pioneering Research And Discovery Of Medicines For Cystic Fibrosis - MarketScreener
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis - Business Wire
Vertex Pharmaceuticals (VRTX) Stock Moves -1.41%: What You Should Know - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise - Insider Monkey
Vertex Pharmaceuticals gets EU nod to expand label for cystic fibrosis treatment - MSN
‘Put On Your Life Vest’: Pharma Tariffs Are Coming - BioSpace
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - MSN
Morgan Stanley Adjusts PT on Vertex Pharmaceuticals to $462 From $459, Keeps Equalweight Rating - MarketScreener
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 41% Undervalued - Yahoo Finance
Vertex raises pay of CEO Reshma Kewalramani by 4% to $21.5M - Fierce Pharma
Vertex non-opioid painkiller Journavx gets mixed ICER review - MSN
Jim Cramer Calls Vertex Pharmaceuticals Incorporated (VRTX) “Terrific” With “Revolutionary Pain Drug” - Insider Monkey
Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires? - Yahoo Finance
Is Vertex Pharmaceuticals Stock a Buy? - MSN
Vertex secures expanded EU approval for Kaftrio - The Pharma Letter
VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe - Yahoo Finance
Jim Cramer Nailed These 11 Stock Picks - Insider Monkey
Vertex to Announce First Quarter 2025 Financial Results on May 5th - BioSpace
Vertex Gains European Approval For Expanded Use Of KAFTRIO In Treating Cystic Fibrosis - Nasdaq
European Commission Expands Approval for Vertex's Kaftrio (VRTX) - GuruFocus
Vertex Pharmaceuticals Says EU Approves Kaftrio Label Expansion in Cystic Fibrosis - MarketScreener
EU approves expanded use of Vertex’s cystic fibrosis drug - Investing.com
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers' - Benzinga
2 Stocks to Buy if You're Worried About a Recession - Yahoo Finance
Vertex Pharmaceuticals Sets Key Q1 2025 Earnings Date: What Investors Must Know - Stock Titan
Vertex Pharmaceuticals: A Look At Their Pain Therapy Program (NASDAQ:VRTX) - Seeking Alpha
Vertex Pharmaceuticals - drugdiscoverytrends.com
10 Best Health Care Stocks to Buy for 2025 - Money/ US News
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
Bank of America Increases Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $567.00 - MarketBeat
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals: How a Human-Centric Digital Strategy Transforms Supply Chain Agility - Logistics Viewpoints -
Wells Fargo Remains a Hold on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals' Human-Centric Approach to Digital Transformation - ARC Advisory
Petri Dish: Vertex halts type 1 diabetes trial; Watertown manufacturer sold - The Business Journals
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS) - The Globe and Mail
Vertex Pharmaceuticals (VRTX): Company Profile, Stock Price, News, Rankings - Fortune
Judge Blocks Vertex From Funding Fertility Preservation Services - Bloomberg Law News
Careers | Inclusion, Diversity and Equity - Vertex Pharmaceuticals
Is Vertex Pharmaceuticals Gaining or Losing Market Support? - Benzinga
Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy? - Insider Monkey
DC court backs HHS in rejecting Vertex's proposed fertility support program for Casgevy patients - Fierce Pharma
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates - TradingView
RBC Adjusts Price Target on Vertex Pharmaceuticals to $420 From $408, Maintains Sector Perform Rating - MarketScreener
Vertex Pharmaceuticals price target raised to $420 from $408 at RBC Capital - TipRanks
0.64%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):